<DOC>
	<DOCNO>NCT00514020</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , oxaliplatin , leucovorin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give fluorouracil together oxaliplatin leucovorin work treat patient metastatic stomach cancer gastroesophageal junction cancer .</brief_summary>
	<brief_title>Fluorouracil , Oxaliplatin , Leucovorin Treating Patients With Metastatic Stomach Cancer Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare response rate patient `` good risk '' genotype ( TSER*2/*2 TSER*2/*3 genotype [ low TS expression ] ) historical control response rate non-genotype selected patient . OUTLINE : This multicenter study . Patients receive oxaliplatin IV 2 hour , leucovorin calcium IV 2 hour , fluorouracil IV 5 minute continuously 46 hour day 1 15 . Courses repeat every 2 week absence unacceptable toxicity disease progression . Available tumor tissue sample assess expression TS mRNA protein level . The result correlate germline tumor TSER genotypes well response study treatment regimen . Polymorphisms gene associate treatment outcome toxicity also assess . After completion study treatment , patient follow periodically 4 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients must histologically cytologically confirm adenocarcinoma stomach gastroesophageal junction Metastatic disease Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No known active brain metastasis Patients treat brain metastasis eligible stable steroid least 30 day PATIENT CHARACTERISTICS : ECOG performance status ≤ 2 ( Karnofsky performance status ≥ 60 % ) Life expectancy ≥ 3 month WBC ≥ 3,000/μL Absolute neutrophil count ≥ 1,500/μL Platelets ≥ 100,000/μL Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) AST ALT ≤ 2.5 x ULN ( &lt; 5 x ULN know liver metastasis ) Creatinine clearance ≤ 1.5 x ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 21 day completion study treatment No history allergic reaction fluorouracil oxaliplatin No concurrent uncontrolled illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : No prior therapy metastatic disease Prior neoadjuvant adjuvant therapy allow diseasefree interval longer 6 month No concurrent chemotherapy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent routine prophylaxis filgrastim ( GCSF ) No concurrent antineoplastic agent , include chemotherapy , radiation therapy , biologic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
</DOC>